Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 773

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 773
---
 all of the shares entitled to vote thereon were present and voted (the “

#### Requisite Majority
”), do hereby irrevocably consent to and approve the adoption of the following resolutions, without a meeting, pursuant to Section 78.320 of Chapter 78 of the Nevada Revised Statutes (the “

#### NRS
”) and the bylaws of the Company (the “

#### Bylaws
”):

WHEREAS , the Company has entered into an Agreement and Plan of Merger, dated as of April 16, 2025, with CHRO Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“ Merger Sub ”), LNHC, Inc., a Delaware corporation ( “ Merger Partner ”) and, solely for the purposes of Article III thereof, Ligand Pharmaceuticals Incorporated, a Delaware corporation, a copy of which has been provided to the undersigned Consenting Stockholders and is attached hereto as Exhibit A (the “ Merger Agreement ”);

WHEREAS , pursuant to the Merger Agreement, Merger Sub will be merged with and into the Company (the “ Merger ”), with Merger Partner continuing as the surviving corporation following the Merger and as a wholly owned subsidiary of the Company (the “ Surviving Corporation ”), upon the terms and subject to the conditions set forth in the Merger Agreement;

WHEREAS , pursuant to the terms and conditions of the Merger Agreement, upon the effective time of the Merger (the “ Effective Time ”), (i) each share of common stock, par value $0.001 per share, of Merger Sub (the “ Merger Sub Common Stock ”) issued and outstanding immediately prior to the Effective Time will be converted into and become one (1) fully paid and nonassessable share of common stock, par value $0.01 per share, of the Surviving Corporation and (ii) each share of common stock, par value $0.01 per share, of Merger Partner (the “ Merger Partner Common Stock ”) other than Merger Partner Common Stock held in treasury immediately prior to the Effective Time will be automatically converted into the right to receive a number of shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company (the “ Series A Preferred Shares ”) equal to the Exchange Ratio (as defined in the Merger Agreement);

WHEREAS , as a condition to closing the Merger, concurrently with the execution and delivery of the